| scholarly article | Q13442814 |
| P50 | author | Egil Lien | Q90239495 |
| P2093 | author name string | Frank M Szaba | |
| Jr-Shiuan Lin | |||
| Lawrence W Kummer | |||
| Stephen T Smiley | |||
| Lawrence L Johnson | |||
| Michelle A Parent | |||
| Lindsey B Wilhelm | |||
| Sara W Montminy-Paquette | |||
| P2860 | cites work | In vivo comparison of avirulent Vwa- and Pgm- or Pstr phenotypes of yersiniae | Q37097219 |
| Vaccines against intracellular bacterial pathogens | Q37206444 | ||
| Cell-mediated protection against pulmonary Yersinia pestis infection | Q39393406 | ||
| Expression of plasminogen activator pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. | Q39573935 | ||
| Antibodies and cytokines independently protect against pneumonic plague. | Q41441607 | ||
| A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. | Q41446828 | ||
| Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection | Q41451306 | ||
| Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response | Q41452286 | ||
| Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection | Q41453869 | ||
| The anti-plague system and the Soviet biological warfare program | Q41454361 | ||
| Yersinia pestis V protein epitopes recognized by CD4 T cells | Q41459022 | ||
| Plague, Democratic Republic of The Congo. | Q41459174 | ||
| Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague | Q41461188 | ||
| Defining the genome content of live plague vaccines by use of whole-genome DNA microarray | Q41461622 | ||
| The SCID/Beige mouse as a model to investigate protection against Yersinia pestis | Q41483548 | ||
| Multidrug resistance in Yersinia pestis mediated by a transferable plasmid | Q41487671 | ||
| Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis | Q41488613 | ||
| A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model | Q41493178 | ||
| Loss of the pigmentation phenotype in Yersinia pestis is due to the spontaneous deletion of 102 kb of chromosomal DNA which is flanked by a repetitive element | Q41505380 | ||
| Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs | Q41551949 | ||
| Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections | Q45738972 | ||
| IMMUNITY IN PLAGUE. ACQUISITIONS SUPPLIED BY 30 YEARS OF WORK ON THE "PASTEURELLA PESTIS EV" (GIRARD AND ROBIC) STRAIN | Q76657056 | ||
| Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine | Q24672915 | ||
| Yersinia pestis--etiologic agent of plague | Q29619320 | ||
| Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates | Q31037921 | ||
| Immune defense against pneumonic plague | Q33584403 | ||
| Human immune response to a plague vaccine comprising recombinant F1 and V antigens | Q33788286 | ||
| Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense | Q33901607 | ||
| Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. | Q34128266 | ||
| Yersinia pestis (plague) vaccines | Q34324211 | ||
| Risk of person-to-person transmission of pneumonic plague | Q34406504 | ||
| Administration of antibody to the lung protects mice against pneumonic plague. | Q34601788 | ||
| Differential clearance and host-pathogen interactions of YopE- and YopK- YopL- Yersinia pestis in BALB/c mice | Q35094337 | ||
| Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. | Q35429159 | ||
| Development of in vitro correlate assays of immunity to infection with Yersinia pestis. | Q35783560 | ||
| Plasmid maintenance systems suitable for GMO-based bacterial vaccines | Q36065368 | ||
| Protection from respiratory virus infections can be mediated by antigen-specific CD4(+) T cells that persist in the lungs | Q36369221 | ||
| Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. | Q36539626 | ||
| Current challenges in the development of vaccines for pneumonic plague | Q36628038 | ||
| Biological safety concepts of genetically modified live bacterial vaccines | Q36713988 | ||
| Effectiveness of live or killed plague vaccines in man. | Q36719644 | ||
| Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine | Q36960814 | ||
| Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection | Q37066697 | ||
| Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration | Q37093215 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Yersinia pestis | Q153875 |
| P304 | page(s) | 4295-4304 | |
| P577 | publication date | 2009-07-20 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague | |
| P478 | volume | 77 |
| Q34778198 | A live attenuated strain of Yersinia pestis KIM as a vaccine against plague |
| Q41398803 | A live attenuated strain of Yersinia pestis ΔyscB provides protection against bubonic and pneumonic plagues in mouse model |
| Q35665414 | A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis |
| Q38386726 | Biosynthetically engineered lipopolysaccharide as vaccine adjuvant |
| Q36646741 | Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium. |
| Q93375305 | Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi improved the protective efficacy of YopE against plague infection |
| Q39736724 | Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis |
| Q34633478 | HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model |
| Q34786724 | IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection |
| Q47293934 | Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague |
| Q36316792 | Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague. |
| Q35530270 | Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague |
| Q36911486 | Intranasal prophylaxis with CpG oligodeoxynucleotide can protect against Yersinia pestis infection |
| Q38113270 | Live-attenuated Yersinia pestis vaccines |
| Q36876293 | Manipulation of Interleukin-1β and Interleukin-18 Production by Yersinia pestis Effectors YopJ and YopM and Redundant Impact on Virulence |
| Q41400297 | Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model |
| Q91826998 | Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection |
| Q36804699 | Pathogenicity of Yersinia pestis synthesis of 1-dephosphorylated lipid A. |
| Q37889155 | Progress on plague vaccine development |
| Q37640118 | Prospects for new plague vaccines. |
| Q89878357 | Protection and Safety Evaluation of Live Constructions Derived from the Pgm- and pPCP1- Yersinia pestis Strain |
| Q37688618 | Rational considerations about development of live attenuated Yersinia pestis vaccines |
| Q90696345 | Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague |
| Q33650538 | TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection |
| Q91904115 | Yersinia pestis Pla Protein Thwarts T Cell Defense against Plague |
| Q35091255 | Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague |
| Q34290878 | Yersinia pestis biovar Microtus strain 201, an avirulent strain to humans, provides protection against bubonic plague in rhesus macaques |
Search more.